Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Combo Product Classification Guidance Doesn't Fix All Existing Problems, Experts Say

Executive Summary

US FDA's tendency to designate products as drugs over devices may remain despite clarifications offered in final guidance.

You may also be interested in...



Combination Product Designations At US FDA Need Faster Appeals, Petition Says

No sponsor is named in the citizen petition, but it was filed on behalf of an applicant that has had an appeal of a designation decision 'under consideration' for 18 months and counting.

Cures Bill Authorizes Inter-Center Institutes, But Will US FDA Create Them?

The agency is still working to get an oncology center of excellence off the ground and has other large pending reorganizations to tackle before it may get to creating additional centers intended to break down device, drug and biologic silos.

Cures Bill Authorizes 'Intercenter Institutes,' But Will US FDA Create Them?

Agency is still working to get oncology center of excellence off the ground and has other large pending reorganizations that could take precedence.

Related Content

Topics

UsernamePublicRestriction

Register

PS121736

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel